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Abstract
Background: Adoptive cell transfer of tumor infiltrating lymphocytes has shown clinical efficacy in the treatment of
melanoma and is now also being explored in other tumor types. Generation of sufficient numbers of effector T cells
requires extensive ex vivo expansion, often at the cost of T cell differentiation and potency. For the past 20 years,
IL-2 has been the key cytokine applied in the expansion of TIL for ACT. However, the use of IL-2 has also led to
collateral expansion of regulatory T cells (Tregs) and progressive T cell differentiation, factors known to limit in vivo
persistence and activity of transferred TIL. The use of alternative T cell growth factors is therefore warranted. Here,
we have compared the effects of IL-2, -15 and −21 cytokines on the expansion and activation of TIL from single-cell
suspensions of non-small cell lung cancer, ovarian cancer and melanoma.
Methods: We applied the K562-based artificial APC (aAPC) platform for the direct and rapid expansion of tumor
infiltrating lymphocytes isolated from primary cancer specimens. These aAPC were engineered to express the Fc-γ
receptor CD32 (for anti-CD3 antibody binding), the co-stimulatory molecule 4-1BBL, and to secrete either IL-2, IL-15
or IL-21 cytokine.
Results: Although IL-2 aAPC induced the greatest overall TIL expansion, IL-21 aAPC induced superior expansion of
CD8+ T cells with a CD27+CD28+ “young” phenotype and superior functional cytotoxic effector characteristics,
without collateral expansion of Tregs.
Conclusion: Our data rationalize the clinical application of IL-21-secreting aAPC as a standardized cell-based
platform in the expansion of “young” effector TIL for ACT.
Background
Effective cancer immunotherapy depends on high enough
frequencies of tumor-specific T lymphocytes with appro-
priate phenotypic characteristics, homing capacities and
potent effector functions [1]. Adoptive cell transfer (ACT)
has been recognized as an effective approach to achieve
this. ACT using naturally-occurring autologous tumor in-
filtrating lymphocytes (TIL) has been studied extensively
in preclinical mouse models and human clinical trials, and
has been shown effective in about half of ACT-treated
metastatic melanoma patients [2]. To generate sufficient
numbers of effector T cells for ACT, extensive ex vivo ex-
pansion of T cells is required. Unfortunately, expansion
often occurs at the expense of T cell differentiation and
potency. Indeed, it was shown that the use of minimally
cultured “young” less-differentiated TIL, with longer telo-
meres and higher levels of the co-stimulatory molecules
CD27 and CD28, is an important factor for success.
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“Young” TIL demonstrated better persistence and subse-
quent anti-tumor activity upon adoptive transfer [3-7]. To
date, IL-2 has been the consummate cytokine used in the
generation of TIL for adoptive transfer [8]. IL-2, which
belongs to the common γ chain family of cytokines, has
been shown to promote T cell activation, proliferation and
survival, and to induce tumor lysis by the expanded lym-
phocytes [9]. Indeed, tumor regressions have been ob-
served upon adoptive transfer of IL-2-expanded TIL [10].
However, IL-2 can also lead to activation-induced cell
death (AICD), progressive differentiation (i.e. less “young”
TIL) and to the induction of suppressive regulatory T cells
(Tregs) [11-13], indicating that IL-2 may also have a nega-
tive impact on the induction of an effective anti-tumor
response.
IL-15 and IL-21 are also common γ chain cytokines that
have been described to play a role in T cell proliferation,
survival and function. IL-15 is involved in the mainten-
ance and expansion of memory CD8+ T cells, NK, NKT
and γδ T cells [14], and IL-21 promotes the function of
effector CD8+ T cells [15-17]. Recent studies in mice have
shown that adoptively transferred T cells demonstrated
superior in vivo persistence and tumor elimination when
pre-treated with either IL-15 or IL-21 [18-21].
Current methodology for the expansion of T cells for
ACT involves the expansion of TIL from small tumor
fragments or biopsies by exposure to IL-2, irradiated allo-
geneic feeder cells and CD3 ligation via an anti-CD3 anti-
body, a process called rapid expansion method (REM)
[22,23]. Despite its potential, REM has been shown to
greatly reduce CD28 and CD27 expression on the ex-
panded TIL, and this is associated with reduced persist-
ence and hence limited anti-tumor activity of the infused
TIL [3,24-27]. Others and we have demonstrated previ-
ously that human peripheral blood derived lymphocytes
can be expanded efficiently by K562 artificial APC (aAPC)
[28-30], a standardized cell-based expansion platform, and
that incorporation of the co-stimulatory molecule 4-1BBL
into these aAPC results in efficient expansion of human
CD8+ T cells with sustained CD28 and CD27 surface ex-
pression [29]. Notably, aAPC also facilitate the expansion
of antigen-experienced TIL for ACT therapy [31].
In this study, we have investigated and compared the
effects of IL-2, IL-15 and IL-21 cytokine on the expansion,
phenotype and function of TIL from NSCLC, OvCa or
melanoma biopsies utilizing aAPC engineered to express
the Fcγ receptor CD32 (for anti-CD3 mAb binding), the
co-stimulatory molecule 4-1BBL and either IL-2, IL-15 or
IL-21. Our findings demonstrate that aAPC engineered to
secrete IL-21 stimulate the preferential expansion of TIL
with particularly attractive traits for ACT, i.e. high rates of
CD8+ T cells with a less differentiated “young” phenotype
and superior cytotoxic effector characteristics as well as
low frequencies of CD4+CD25hiFoxP3+ Tregs.
Materials and methods
Patients and sampling of tumor biopsies
Fresh tumors were collected from patients with NSCLC or
OvCa patients after obtaining appropriate informed con-
sent under Institutional Review Board-approved protocols.
The tumor lesions were collected in cold, sterile RPMI
1640 medium supplemented with 20% FCS, 50 μg/ml Gen-
tamycine sulphate (Sigma, St. Louis, MO) and 12.5 μg/ml
Amphotericin B (Gibco/Invitrogen, Carlsbad, CA) (wash
medium). The tumor lesions were washed three times with
wash medium, after which they were cut into small pieces
with a surgical blade. Next, the cut tumor was incubated
at 37°C on a shaker with digestion buffer containing
0.66 mg/ml Collagenase A (Sigma) and 0.33 mg/ml DNAse
I (Roche, Indianapolis, IN). After 1 hour, the digested
tumor sample was pushed through a 70 μm filter, washed
2 times with PBS and used for further evaluation and cul-
ture. HLA-A2+ melanoma tumor samples were selected
from a previous study of Active Specific Immunotherapy
(ASI) with autologous whole-cell tumor vaccines, carried
out at the VU Medical Center. Tumor dissociation and
cryopreservation methodologies for these samples were
previously reported [32].
Generation and culturing of lentivirally transduced K562
artificial APC
The different human K562 aAPC lines were generated and
cultured as described [29]. In brief, K562 cells (American
Type Culture Collection, Manassas, VA) were transduced
with the lentiviral vector 4-1BB-pCLPS, after which cells
with high 4-1BBL expression were cloned using high-
speed MOFLO sorting (Cytomation, Fort Collins, CO).
Next, 4-1BBL-expressing K562 aAPC were transduced
with CD32-pCLPS, CD32-IRES-IL-2-pCLPS, CD32-IRES-
IL-15-pCLPS or CD32-IRES-IL-21-pCLPS to generate no
cytokine, IL-2, IL-15 or IL-21-producing K562 aAPC
(hereafter referred to as no cytokine, IL-2, IL-15 or IL-21
aAPC, respectively). K562 aAPCs were cultured in AIM-V
(Gibco BRL/Life Technologies, Grand Island, NY) contain-
ing 3% human AB serum (Valley Biomedical, Winchester,
VA), 100 U/ml penicillin G sodium, 100 μg/ml strepto-
mycin sulphate and 2 mM L-glutamin (Glutamax; all from
Gibco/Invitrogen). Cytokine production by the aAPC was
confirmed by ELISA (IL-15: Genprobe, San Diego, CA and
IL-21: Biolegend, San Diego, CA) or cytometric bead array
(BD Biosciences, Mountain view, CA). To this end, the
aAPC were cultured overnight at 500,000 cells/ml, after
which the supernatants were frozen until use.
Polyclonal stimulation and expansion of tumor infiltrating
lymphocytes
T cells were cultured in RPMI 1640 medium (Gibco/
Invitrogen) supplemented with 5% human AB serum,
100 U/ml penicillin G sodium, and 100 μg/ml streptomycin
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sulphate and 2 mM L-glutamin (complete medium). Before
stimulation, no cytokine, IL-2-, IL-15- and IL-21 aAPC
were lethally irradiated with 100 Gy, washed and resus-
pended at 0.5 × 106/ml in RPMI complete medium. Next,
500,000 aAPC were added per well in a 24 well plate and
loaded with 0.5 μg/ml anti-CD3 antibody (OKT3; Or-
thoclone, Bridgewater, NJ) for 15 minutes at room tem-
perature. The tumor cell suspensions were resuspended at
2 × 106/ml in RPMI complete medium and 1.0 ml of cells
was added drop wise to the aCD3-loaded aAPCs. T cell
stimulation cultures were monitored for cell volume and
enumerated on a Coulter Multisizer 3 (Beckman Coulter,
Fullerton, CA) every 2–3 days. Cells were re-stimulated at
8–11-day intervals, when the expansion rate reached a plat-
eau and/or the mean lymphocyte volume decreased to pre-
expansion size. After one and/or two rounds of stimulation,
the expanded TIL were used for further phenotypic and
functional analysis.
Antibodies, Tetramers and Flow Cytometry
Fluorescein isothiocyanate- (FITC), phycoerythrin- (PE),
peridinin chlorophyll protein-Cy5.5- (PerCP-Cy5.5), allo-
phycocyanin- (APC), or Alexafluor-488- (AF-488)-labeled
Abs directed against human CD3, CD4, CD8, CD45RA,
CD45RO, CD27, CD28, CD62L, CD56, CD19, CD14,
CD25 and Granzyme B (all from BD Biosciences/Phar-
mingen), CCR7 (R&D systems, Minneapolis, MN), FoxP3
(Biolegend), Perforin (Ebiosciences, San Diego, CA) and
matched isotype control antibodies, and PE- and/or APC-
labeled HLA-A2 tetramer presenting melanoma-associated
epitopes GP100154–162, GP100209–217, GP100280–288, and
MART-126L–35 (all kindly provided by Dr. John Haanen,
Netherlands Cancer Institute, Amsterdam, the Netherlands)
were used for flowcytometric analysis. Antibody and/or
tetramer staining was performed in PBS supplemented with
0.1% BSA and 0.02% Sodium-Azide for 30 minutes at 4°C
or 15 min at 37°C, respectively. Stained cells were ana-
lyzed on a FACScalibur (BD Biosciences). To exclude dead
cells in flow cytometric tetramer analysis, 0.5 μg/ml Propi-
dium Iodide (ICN Biomedicals, Zoetermeer, The Netherlands)
was used. The number of CD8+ T cells measured was at
least 100,000. T cell cultures were considered tetramer
positive when tetramer + cells were equal to or exceeded
20 cells per 1 × 10e5 CD8+ T cells (0.02%). All flow cyto-
metry data were analyzed with Cell Quest software (BD
Biosciences).
Cytotoxicity analysis
Cytolytic activity of the expanded TIL was analyzed by
flow cytometry-based re-directed cytotoxicity assay. To
this end, KT32/4-1BBL aAPC were pulsed with 1 μM of
CFSE (Sigma), lethally irradiated with 100 Gy, and resus-
pended in RPMI supplemented with 5% hAB serum (ICN
Biochemicals). Next, KT32/4-1BBL aAPC were loaded
with 0.5 μg/ml anti-CD3 antibody (OKT3; Orthoclone,
Bridgewater, NJ) for 15 minutes at room temperature,
after which they were cultured in triplicate at a 1:2 ratio
with aAPC-expanded CD8+ T cells. The CD8+ T cells were
isolated from expanded TIL suspensions by magnetic cell
sorting via negative selection using a CD8 T cell isolation
kit (Miltenyi Biotec, Bergisch Gladbach, Germany). After
20 hours, the cells were harvested, and the percentage of
cell kill was determined by 7-AAD staining (BD Pharmin-
gen). Specific killing was determined as the percentage of
7-AAD positive cells within CFSE+ target cells and calcu-
lated as follows: percentage experimental 7-AAD+ cells
minus percentage CFSE+/7-AAD+ target cells in cultures
without added effector T cells (i.e. spontaneous/base level
cell death).
IFN-γ ELISA for T cell function
Tumor reactivity of IL-2, IL-15 and IL-21-aAPC-expanded
CD8+ T cells was assessed by IFN-γ secretion. To this end,
unexpanded tumor cell suspension was thawed, and CD45+
cells were depleted by magnetic cell sorting using CD45-
microbeads (Milteny Biotec; according to manufacturer’s
instruction). Next, 50,000 autologous tumor cells were cul-
tured for 20 hours with 100,000 CD8+ T cells in triplicate
(isolated through magnetic cell sorting as described above),
after which supernatants were harvested and frozen. IFN-γ
levels were determined by ELISA (sensitivity 1 pg/ml)
according to manufacturer's instruction (M1933, Sanquin,
Amsterdam, The Netherlands). Indicated values represent
the mean cytokine concentration (pg/ml) ± SD of triplicate
wells.
Statistical Analysis
Repeated measures ANOVA was used to statistical signifi-
cance of differences between groups with a Tukey post test,
if data followed Gaussian distribution. If the data did not
pass normality test, a Friedman test was used, followed by
a Dunn’s post test. Findings were considered statistically
significant when p-values were < 0.05, as indicated with
asterisks (* p < 0.05, ** p < 0.01), *** p < 0.001). Statistical
analyses were performed using GraphPad Prism software
(version 5, 2007).
Results
Characterization of K562 aAPC
Expression of the Fcγ receptor (CD32) and the co-
stimulatory molecule 4-1BBL was confirmed by flow cyto-
metry for the aAPC employed (data not shown). The over-
night (18 h) secreted amounts of IL-2, IL-15 and IL-21 by
the corresponding aAPC were determined by ELISA as
17.0, 2.0 and 11.1 ng/ml per 500,000 cells/ml respectively,
whereas the “no cytokine” aAPC did not produce any of
the cytokines.
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TIL suspensions
Prior to expansion, single-cell suspensions of enzymati-
cally-digested NSCLC and OvCa tumors were character-
ized by flow cytometry. As shown in Additional file 1:
Figure S1, the leukocyte infiltrate ranged between 24 and
89% of the total cellular fraction, with a mean of 67% for
both NSCLC and OvCa tumor digests, as indicated by
CD45 staining. Moreover, NSCLC and OvCa CD45+ leu-
kocytes contained similar levels of CD3+ T cells, B lym-
phocytes, NK cells, monocytes and regulatory T cells. The
epithelial antigen-positive tumor fraction ranged between
1.4 and 29.2% of the overall NSCLC and OvCa cell
population.
Numerical T cell expansion
TIL were expanded from the tumor cell suspensions by
stimulation with IL-2-, IL-15-, IL-21- or no cytokine-
expressing aAPC, after which phenotype and function of
the various cytokine-expanded TIL were analyzed. Com-
paring the numbers of T cells expanded by IL-2, IL-15-,
IL-21- or no cytokine-producing aAPC revealed striking
differences. As shown in Figure 1A, total cell expansion
was significantly higher with IL-2 aAPC compared with
no cytokine-, IL-15- or IL-21 aAPC. Furthermore, IL-2
aAPC-expanded TIL contained more CD3+ T cells and
significantly less CD3-CD56+ NK cells as compared with
IL-15 or IL-21 aAPC-expanded TIL (Figure 1B and C,
respectively). Yet, IL-21 aAPC-expanded TIL contained
significantly more CD8+ T cells as compared with IL-2-, IL-
15- and no cytokine aAPC-expanded TIL (Figure 1D).
Effect of T cell expansion on phenotype
The expanded TIL were analyzed after 2 rounds of ex-
pansion for their (effector/memory) differentiation stage
and the presence of CD4+FoxP3+ suppressive regulatory
T cells. As shown in Figure 2A and B, IL-21 aAPC-
expanded CD8+ and CD4+ T cells exhibited a “younger”
less differentiated phenotype as they comprised significantly
more CD27+CD28+ double positive cells as compared with
IL-2, IL-15 and no cytokine aAPC-expanded TIL. Further-
more, IL-21 aAPC co-expanded less CD4+FoxP3+ cells.
Both the percentage of FoxP3+ cells within the CD4 popu-
lation (Figure 2C) and within the total TIL population
(Figure 2D) from IL-21 aAPC-expanded cultures were
reduced compared to all other conditions. Since activated T
cells can also transiently express FoxP3, FoxP3 analysis in
expanded TIL was performed when TIL returned to quies-
cence, i.e. when they had returned to their pre-expansion
cell size, as measured by the Coulter Multisizer 3 cell sizing
device.
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Figure 1 Efficiency of tumor infiltrating lymphocytes (TIL) expansion via IL-2, IL-15, IL-21 or no cytokine aAPC. NSCLC, OvCa and
melanoma (mel)-derived TIL were expanded by stimulation with IL-2, IL-15, IL-21 or no cytokine-producing aAPC and used for further phenotypic
analysis by flow cytometry after two rounds of stimulation. A) Fold expansion of total number of TIL cells in the IL-2, IL-15, IL-21 or no cytokine
aAPC-expanded cultures is depicted for 16 NSCLC/OvCa/mel patients. B) Percentage of CD3+ T cells within the total cell population and
C) percentage of CD3-CD56+ NK cells is shown for 12 patients. D) Percentage of CD8+ T cells within the CD3+ population is shown for 14
patients. Differences were compared using repeated measures ANOVA’s with a Tukey post test when data followed Gaussian distribution and by
using a Friedman test with a Dunn’s post test when data did not pass the normality test. Differences were considered significant when p < 0.05,
as indicated with an asterisk (* p < 0.05, ** p < 0.01), *** p < 0.001).
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Impact of aAPC-based expansion on T cell function
To assess the effects of the different cytokines during
cell-based expansion on T cell function, the IL-2, IL-15
and IL-21 aAPC-expanded TIL were subjected to further
functional analysis. The expanded TIL were analyzed for
their cytotoxic potential by granzyme B and perforin
staining. IL-21 aAPC expanded CD4+ (Additional file 1:
Figure S2A) and CD8+ TIL (Figure 3) expressed signifi-
cantly more perforin and granzyme B compared with
the IL-2, IL-15 and no cytokine aAPC expanded TIL,
suggestive of their higher cytotoxic potential. This was
confirmed in an in vitro redirected killing assay employ-
ing anti-CD3-loaded K562 as target cells. As shown in
Figure 4A, CD8+ T cells obtained from IL-21 aAPC-
expanded melanoma TIL cultures exhibited significantly
higher cytotoxic activity compared with CD8+ T cells
obtained from IL-15 and IL-2 aAPC expanded TIL. Of
note, cytotoxicity was TCR/CD3 complex-dependent, as
the killing was reduced to near background levels in the
absence of the CD3 antibody OKT3.
To assess whether the aAPC-expanded TIL retained
tumor recognizing capabilities following expansion, TIL
obtained from four HLA-A2+ melanoma patients were
analyzed by HLA-A2 tetramer analysis. As shown in
Table 1, Mart-126L- and/or GP100154/209/280-specific CD8
+
T cells could be detected to similar levels in fresh (i.e. unex-
panded) and IL-2, IL-15 and IL-21 aAPC expanded TIL
samples, indicating that tumor antigen specificity was
maintained after aAPC-mediated expansion.
For one of these patients (mel65), viable and MHC class
I expressing autologous tumor cells were available for
functional testing by IFNγ secretion assay. Anti-tumor ef-
fector function of the aAPC-expanded TIL could be con-
firmed for this patient, as demonstrated by IFNγ secretion
after co-culture with autologous tumor cells (Figure 4B).
Moreover, this tumor recognition was TCR dependent, as
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Figure 2 Frequencies of CD27+CD28+ and CD4+FoxP3+ T cells in IL-2, IL-15, IL-21 or no cytokine aAPC-expanded TIL. NSCLC/OvCa/mel-
derived TIL were expanded by stimulation with IL-2, IL-15, IL-21 or no cytokine producing aAPC and used for further phenotypic and functional
analysis. Percentage of CD27+CD28+ T cells was determined after two stimulations, and percentage of CD4+FoxP3+ T cells was determined after
one or two stimulations by flow cytometry. Percentages of CD27+CD28+ is given for 13 NSCLC/OvCa/mel patients within A) the CD3+CD8+ T cell
population and B) the CD3+/CD4+ T cell population. Percentage of suppressive FoxP3+ T cells is given for 13 patients C) as percentage of FoxP3
within CD4+ T cell population or D) as percentage of CD4+FoxP3+ cells within the total TIL population. Differences were compared using
repeated measures ANOVA’s with a Tukey post test when data followed Gaussian distribution and by using a Friedman test with a Dunn’s post
test when data did not pass the normality test. Differences were considered significant when p < 0.05, as indicated with an asterisk (* p < 0.05,
** p < 0.01), *** p < 0.001).
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the IFNγ secretion was reduced to background levels in
the presence of an MHC class I blocking antibody. Interest-
ingly, the IL-21 aAPC expanded CD8+ T cells demonstrated
superior functional tumor recognition, with significantly
higher IFNγ release levels than the CD8+ T cells expanded
by IL-2 and IL-15 aAPC.
In summary, our findings demonstrate that IL-21 aAPC
are preferred for the expansion of T cells for adoptive T cell
transfer, as they yielded CD8+ T cells with superior cyto-
toxic effector characteristics and phenotypic traits con-
sistent with greater in vivo persistence, while minimizing
collateral Treg induction.
Discussion
ACT therapy using autologous TIL or gene-modified T
cells has demonstrated clinical efficacy in the treatment
of cancer [2,33,34]. Generation of sufficient numbers of
tumor-specific T cells with appropriate phenotype, hom-
ing capacities and sufficient effector functions are im-
portant factors for success. The current approach for the
expansion of TIL for ACT involves the expansion of TIL
from small tumor fragments or biopsies by exposure to
high-dose IL-2, irradiated feeders and CD3 ligation via
an anti-CD3 antibody (also called REM)[22,23]. Yet,
REM has been shown to greatly reduce CD28 and CD27
expression of the expanded TIL, and this is associated
with reduced persistence and subsequent limited anti-
tumor activity of the infused TIL [24-27]. We recently
showed that the aAPC platform induces numerically
similar expansion of TIL compared with REM, and these
TIL have a “young” CD27+CD28+ phenotype, are enriched
for CD8+ T cells, contain fewer Tregs and are tumor-
reactive [31]. In the current study, we have compared the
effects of the common γ chain cytokines IL-2, IL-15, and
IL-21 on the expansion and activation of TIL using this
aAPC platform. Our results show that IL-21-transduced
aAPC induced preferential expansion of CD8+ T cells
from TIL, with a “young” and a superior cytotoxic pheno-
type and function without collateral expansion of Tregs.
Notably, these favorable features were enhanced relative
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Figure 3 Cytotoxic capacity of TIL expanded with IL-15, IL-21 or no cytokine producing aAPC. Percentage of granzyme B- or perforin-
expressing CD8+ T cells was determined by flow cytometry. A) Dot plots with percentages of granzyme B+ cells (top panel) and perforin+ cells
(bottom panel) within the CD8+ T cell population are shown for a representative patient. B) Percentage of granzyme B+ cells (left) and perforin+
cells (right) within the CD8+ T cell population are shown for 12 patients. Differences were compared using repeated measures ANOVA’s with a
Tukey post test when data followed Gaussian distribution and by using a Friedman test with a Dunn’s post test when data did not pass the
normality test. Differences were considered significant when p < 0.05, as indicated with an asterisk (* p < 0.05, ** p < 0.01), *** p < 0.001).
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Figure 4 Cytotoxic and tumor-recognizing capacity of TIL expanded with IL-15, IL-21 or no cytokine producing aAPC. Cytotoxic capacity
of the IL-2, IL-15 and IL-21 aAPC-expanded TIL was determined by flow cytometry-based re-directed cytotoxicity assay. To this end, CFSE- and
anti-CD3-pulsed no cytokine aAPC cells were cultured in a 1:2 ratio in triplicate for 20 hours with CD8+ T cells derived from IL-2, IL-15 or IL-21
aAPC-expanded total TIL, after which percentage of killing was determined by 7-AAD staining. A) Data is presented as percentage of 7-AAD+
target cells for three patients. B) MHC-I restricted autologous tumor recognition of expanded TIL from one donor was determined by IFN-γ
secretion assay. To this end, autologous/CD45-depleted tumor cells were cultured in a 1:2 ratio in triplicate for 20 hours with CD8+ T cells derived
from IL-2, IL-15 or IL-21 aAPC-expanded total TIL in the presence of either irrelevant IgG2a antibody (left) or anti-MHC class I blocking antibody
(w6/32; right), after which supernatants were harvested and tested by IFN-γ ELISA. Differences were compared using repeated measures ANOVA’s
with a Tukey post test, and considered significant when p < 0.05, as indicated with an asterisk (* p < 0.05, ** p < 0.01), *** p < 0.001).
Table 1 Tetramer reactivity
Patient Epitope Tetramer-positivity*
Prior to expansion IL-2 aAPC expanded IL-15 aAPC expanded IL-21 aAPC expanded
Mel135 MART-1-26L-35 0.29
† 0.17 0.20 0.31
GP100-154–162/209–217/280–288
‡ n.t. 0.03 0.12 0.13
Mel44 MART-1-26L-35 n.t. 0.01 0 0.02
GP100-154–162/209–217/280–288 n.t. 0 0 0
Mel65 MART-1-26L-35 n.t. 2.23 2.20 1.14
GP100-154–162/209–217/280–288 n.t. 0.03 0.03 0.45
Mel84 MART-1-26L-35 0.14 0.10 0.05 0.02
GP100-154–162/209–217/280–288 0 0.01 0 0
*Percentage tetramer + cells within CD8+ population.
‡Pool of 3 GP100-specific tetramers.
† Response was considered positive when ≥0.02% of CD8+ T cells expressed the specific TCR (depicted in bold).
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to those observed following the parental aAPC and
exceeded those of IL-2 and IL-15 aAPC. These findings
strongly support the clinical application of IL-21 aAPC in
the expansion of effector TIL for ACT.
For the last 20 years, IL-2 has been the key cytokine in
the generation of TIL for ACT [8]. However, IL-2 may
also lead to the expansion/induction of suppressive
Tregs, and this can have a detrimental effect on the anti-
tumor potency of the expanded TIL. Here we found that
indeed CD4+FoxP3+ T cells co-expand when making use
of the aAPC platform. Interestingly, co-expansion of
these CD4+FoxP3+ T cells was nearly abrogated in IL-21
aAPC-expanded TIL, suggesting a minimally suppressive
TIL phenotype. The latter was in line with findings from
others describing a suppressive role for IL-21 on Foxp3
expression and regulatory T cell expansion [17,35]. Of
note, although FoxP3 expression is generally associated
with natural Tregs (nTregs), it has also been described
to be transiently upregulated in activated effector T cells,
and importantly, this up-regulation has not been asso-
ciated with suppressive function [36-38]. We cannot rule
out that (part of ) the CD4+FoxP3+ T cells are actually
activated, thereby transiently expressing FoxP3. How-
ever, all analyses were performed when TIL had become
quiescent and had returned to their pre-expansion size
(as measured by the Coulter Multisizer 3 cell sizing de-
vice), making the relation between FoxP3 and activation
less likely.
As described, one of the major problems that may
limit tumor regression and durable clinical responses
after ACT is the lack of persistence of TIL following in-
fusion. Ex vivo expansion of TIL with the IL-2-based
systems greatly reduces CD27 and CD28 expression,
resulting in reduced persistence and subsequent limited
anti-tumor activity in vivo [24-27,39]. In keeping with
findings from others for IL-21 [18,26], IL-21 aAPCs-
expanded T cells expressed significantly more CD27 and
CD28, indicating that they exhibit a “younger” less dif-
ferentiated phenotype, suggesting that they might persist
longer in vivo.
Besides the maintenance and expansion of memory
CD8+ T cells, NKT cells and γδ T cells [14], IL-15 has also
been described to play an important role in the differenti-
ation and expansion of NK cells [40-42]. This is in keeping
with our observation of increased levels of CD3-CD56+
NK cells in the IL-15 aAPC-expanded TIL. The effect of
IL-21 on NK cells is not completely elucidated yet. Ini-
tially, IL-21 was linked to a regulatory role in NK cell
function [43], yet subsequent studies have described it as
both NK activating and suppressive [44,45]. Here we
found a trend towards increased frequencies of NK cells
after expansion by IL-21 aAPC, suggesting that IL-21 can
enhance proliferation and/or survival of NK cells. More-
over, we found that perforin expression was increased in
the NK cells expanded with IL-21 aAPCs, which con-
trasted with NK cells expanded by IL-15 aAPC (Additional
file 1: Figure S2B).
In keeping with findings by others for IL-21, expansion
of TIL with IL-21 aAPC generates T cells with greater per-
forin and granzyme B levels and superior cytotoxic activity
[46,47]. The latter is indicative of superior cytolytic and
tumor recognizing capacity after transfer. Superior cyto-
toxic activity of the IL-21 aAPC expanded TIL was con-
firmed in a redirected killing assay. Although tested in
only one patient, superior MHC-I restricted anti-tumor
effector activity of the IL-21 aAPC expanded CD8+ T cells
could also be confirmed by IFN-γ secretion upon expos-
ure to autologous melanoma cells.
We demonstrated recently that tumor antigen-specific
T cells were maintained after aAPC/exogenous IL-2-
based expansion of TIL [31]. In line with this, compar-
able frequencies of MART-1-26L and GP100-154/209/280
specific CD8+ T cells were detectable between fresh, and
IL-2, IL-15 and IL-21 aAPC-expanded TIL. These data
indicate that the use of alternative common γ-chain sig-
naling cytokines (i.e. IL-15 or IL-21) does not signifi-
cantly alter the frequency of tumor-reactive CD8+ T cells
in the TIL suspension.
As described, the current approach for the expansion of
TIL for ACT involves expansion by making use of standard
REM with high-dose IL-2 [22,23]. We recently described
that the level of TIL expansion achieved using aAPC with
exogenous IL-2 is similar to that attained by standard REM
[31]. In the current study, we could not make such com-
parison as standard REM was not included in our experi-
ments. As described, standard REM has been shown to
induce 500-2000-fold expansion of TIL in 14 days [3,4,23],
and this is 3–10 fold higher than achieved by our IL-2-
secreting aAPC. This may be explained by the lower levels
of biologically active units secreted by the IL-2-aAPC,
which was determined at 2200 U/ml (range 2100–2300 U/
ml) by an HT2-based reporter bioassay (data not shown;
[48,49]), as compared to the 6000 U/ml generally used in
rapid expansion TIL cultures. In addition, differences in
the preparation of the tumor cell suspensions, i.e. TIL
obtained after enzymatic digestion or after 1–2 weeks
culture of tumor fragments in high dose IL-2 for the
aAPC and REM expansion platforms respectively, may
also be of influence. Therefore, to further substantiate
our findings on the suitability/applicability of the IL-21
aAPC platform for ACT therapy, a head-to-head com-
parative analysis between the standard REM and the IL-21
aAPC platform is warranted in further studies.
Conclusion
In this study, we show that IL-21 promotes the expansion
of CD8+ T cells from TIL with a less differentiated “young”
phenotype, superior cytotoxic effector characteristics, and
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low collateral Treg numbers. We conclude that IL-21
aAPC represent a promising platform for the expansion of
TIL for use in clinical ACT trials.
Additional file
Additional file 1: Figure S1. Phenotypic analysis of NSCLC and OvCa
tumor digests. Single cell suspensions were prepared from NSCLC and
OvCa tumor samples through enzymatic digestion. Tumor digests were
characterized by flowcytometry. Percentage of tumor cells (Epithelial
antigen+ (Ep.Ag+)), white blood cells (CD45+), and CD3+ T cells, CD4
+FoxP3+ regulatory T cells, CD3-CD56+ NK cells, CD14+ monocytes and
CD19+ B cells within total cell suspension is given for A) 11 NSCLC
samples and B) five OvCa samples. Figure S2. Cytotoxic capacity of TIL
and NK cells co-expanded with IL-15, IL-21 or no cytokine producing
aAPC. A) Percentage of granzyme B- or perforin-expressing CD4+ T cells
was determined by flow cytometry. Percentage of granzyme B+ cells
(left) and perforin+ cells (right) within the CD4+ T cell population is
shown for 12 patients. B) Percentage of perforin+ cells within the CD3
+CD56- NK cell population is shown for six patients. Differences were
compared using repeated measures ANOVA’s with a Tukey post test
when data followed Gaussian distribution and by using a Friedman test
with a Dunn’s post test when data did not pass the normality test.
Differences were considered significant when p<0.05, as indicated with
an asterisk (* p<0.05, ** p<0.01), *** p<0.001).
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